Neuromyelitis Optica Spectrum Disorder Clinical Characteristics

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory condition predominantly affecting the optic nerves and spinal cord, marked by recurrent episodes of optic neuritis and transverse myelitis. The presence of antibodies against aquaporin-4 (AQP4-IgG) defines a distinct immunopathological subgroup, although seronegative cases with myelin oligodendrocyte glycoprotein antibody (MOG-IgG) have also been recognised. Clinical manifestations range from visual loss and limb weakness to brainstem syndromes such as area postrema syndrome, where patients experience intractable nausea or hiccups. Disease onset spans a broad age range, with some studies highlighting late-onset presentations beyond 75 years and others emphasising young adult cohorts. Relapse frequency and severity drive cumulative disability, often assessed by the Expanded Disability Status Scale (EDSS). Advances in imaging have delineated characteristic lesion patterns, including longitudinally extensive transverse myelitis and distinctive brain lesions in the dorsal medulla or periependymal regions. Early diagnosis and tailored immunosuppressive strategies are critical to limit irreversible impairment, yet predictors of relapse, visual disability and long-term motor outcomes remain under active investigation to inform individualised treatment pathways.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Neuromyelitis Optica Spectrum Disorder Clinical Characteristics publication trend

The graph below shows the total number of articles in neuromyelitis optica spectrum disorder clinical characteristics across all publications each year (not limited to Nature Index journals).

Technical terms

Aquaporin-4 antibody (AQP4-IgG): Autoantibody directed against the water channel protein aquaporin-4 on astrocytes, a serological marker defining NMOSD.

Expanded Disability Status Scale (EDSS): A standardised scale ranging from 0 (normal neurological function) to 10 (death due to neurological disease), used to quantify disability in demyelinating disorders.

Optic neuritis: Inflammatory demyelination of the optic nerve causing acute visual impairment, often painful eye movements and reduced acuity.

Transverse myelitis: Focal inflammatory lesion spanning three or more spinal segments, presenting with bilateral motor, sensory and autonomic dysfunction.

Area postrema syndrome: Clinical manifestation characterised by uncontrollable nausea, vomiting or hiccups due to inflammation of the dorsal medulla oblongata.

References

1. Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. Journal of Neurology (2015).
2. Visual disability in neuromyelitis optica spectrum disorders: prognostic prediction models. Frontiers in Immunology (2023).
3. Characteristics of recurrence in area postrema-onset NMO spectrum disorder - a retrospective cohort study. BMC Neurology (2024).
4. Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models. Frontiers in Immunology (2022).